Vicor Technologies (VCRT) began generating revenue in January 2010 after 10 years as a developmental company. Risks still abound but, in our opinion, are acceptable given the potential for sales and profitability to ramp rapidly.
Early indications suggest the PD2i Analyzer has received a positive response from physicians although unit placements have been well below our initial expectations. Financial condition is a concern, although significantly mitigated by management s ability to continue to raise financing.
We expect the company to become cash flow positive in 2013. We maintain our Outperform rating. Our near-term price target is $1.07.
VICOR TECHNOLOG (VCRT): Free Stock Analysis Report
Zacks Investment Research
